nsd

Lem-14-1189, a LEM-14 derivative, is a potent NSD inhibitor of the nuclear receptor binding SET domain, and has inhibitory effects on NSD1, NSD2, and NSD3, with IC50 of 418 μM, 111 μM, and 60 μM, respectively. LEM-14-1189 has potential anticancer activity and can be used to study multiple myeloma (MM) and diseases of the blood system.

NSD-IN-4 (Compound A8) is a potent and orally active inhibitor of NSD3, inducing apoptosis in a dose-dependent manner. It demonstrates significant antitumor activity against lung squamous cell carcinoma.

NSD-1034 is an amino acid decarboxylase inhibitor.

NSD-IN-3 (compound 3) serves as a potent inhibitor of the nuclear receptor binding SET domain (NSD). It effectively targets NSD2-SET and NSD3-SET, displaying IC 50 values of 0.81 μM and 0.84 μM, respectively. This compound also impedes the dimethylation of histone H3K36 and suppresses the expression of genes targeted by NSDs in non-small cell lung cancer cells. Furthermore, NSD-IN-3 promotes s-phase cell cycle arrest and induces apoptosis [1].

NSD2-PWWP1-IN-3 (compound 36) is an effective inhibitor of NSD2-PWWP1, with an IC50 value of 8.05 µM. It has potential applications in cancer research.

NSD2-PWWP1-IN-2 (compound 33) is a potent NSD2-PWWP1 inhibitor, exhibiting an IC50 value of 1.49 µM, indicating its potential utility in cancer research.

NSD2-PWWP1-IN-1 (compound 31) is a potent inhibitor of NSD2-PWWP1 with an IC50 value of 0.64 µM, demonstrating potential applications in cancer research.

Aldrin-transdiol is a metabolite of dieldrin. Aldrin-transdiol may be used in insecticides.

Transdermal Peptide is a 11-amino acid peptide, binds to Na+ K+-ATPase beta-subunit (ATP1B1), and enhances the transdermal delivery of many macromolecules. Transdermal Peptide (TD1) binds to ATP1B1, and mainly interacts with the C-terminus of ATP1B1 in yeast and mammalian cells. The interaction affects the expression and localization of ATP1B1 and epidermal structure, but can be antagonized by the exogenous competitor ATP1B1 or be inhibited by ouabain. Inhibition of Transdermal Peptide binding to ATP1B1 causes decreased delivery of macromolecular drugs across the skin[1]. [1]. Wang C, et al. Role of the Na(+) K(+)-ATPase beta-subunit in peptide-mediated transdermal drug delivery. Mol Pharm. 2015 Apr 6;12(4):1259-67.

Transdermal Peptide TD-1 HCl is a novel peptide for enhanced transdermal drug delivery that facilitates the penetration of the skin barrier by several drugs and large hydrophilic proteins, such as insulin and human growth hormoneb.

Transdermal Peptide Disulfide TFA (TD 1 Disulfide(peptide) TFA), an 11-amino acid peptide, specifically binds to the Na+ K+-ATPase beta-subunit (ATP1B1), primarily interacting with its C-terminus, and enhances the transdermal delivery of various macromolecules[1].

NSD2-IN-1 (compound 38) is a potent and highly selective inhibitor of NSD2-PWWP1 (nuclear receptor-binding SET domain 2-PWWP1), with an IC50 value of 0.11 μM. By binding to NSD2-PWWP1, NSD2-IN-1 influences gene expression regulated by NSD2, resulting in apoptosis and cell cycle arrest [1].

NSD3-IN-1, a histone methyltransferase NSD3 inhibitor, demonstrates an IC50 of 28.58 μM.

NSD3-IN-2, a potent inhibitor of NSD3, exhibits an IC50 value of 17.97 μM. It effectively inhibits the growth and proliferation of non-small cell lung cancer (NSCLC) cell lines, including H460, H1299, and H1650, demonstrating significant anticancer activity.

NSD3-IN-3, a potent inhibitor of NSD3, demonstrates significant anticancer activity by inhibiting the growth and proliferation of the non-small cell lung cancer cell line H460, with an IC50 value of 1.86 μM.

NSD2-IN-4 is a potent, selective inhibitor of the NSD2-SET domain, showing promise for the treatment of diseases related to NSD2 [1].

PROTAC NSD3 degrader-1 (compound 56) is a targeted degradation agent for the Nuclear receptor binding SET domain protein NSD3. It effectively induces NSD3 degradation in NCI-H1703 and A549 lung cancer cell lines, with DC50 values of 1.43 and 0.94 μM, respectively. Additionally, it hinders H3K36 methylation, triggers apoptosis, arrests the cell cycle, and diminishes the expression of NSD3-related genes, including CDC25A, ALDH1A1, and IGFBP.

(E)-6,7-transdihydroxyligustilide is a natural product that can be used in related research in the field of life sciences. Its product number is TN8590.

Transdermal Peptide TFA (TD 1 Peptide TFA) is an 11-amino acid polypeptide that binds to Na+/K+ -atpase beta-subunit (ATP1B1) and interacts with the C terminal of ATP1B1.Transdermal Peptide TFA can enhance the transmission of some large molecules in the s

Transdermal Peptide (TD 1 peptide) is a 11-amino acid peptide, binds toNa+ K+-ATPase beta-subunit (ATP1B1), and mainly interacts with the C-terminus of ATP1B1. Transdermal Peptide can enhance the transdermal delivery of many macromolecules.Transdermal Pep

Transdermal Peptide acetate(888486-23-5 free base) (TD 1 (peptide) acetate) is a 11-amino acid peptide, binds toNa+ K+-ATPase beta-subunit (ATP1B1), and mainly interacts with the C-terminus of ATP1B1. Transdermal Peptide can enhance the transdermal delivery of many macromolecules.Transdermal Peptide TD 1 Amide is novel peptide designed to enhance transdermal drug delivery.

The signal transducer and activator of transcription 6 fragments is a peptide with the sequence H2N-Ser-Tyr-Trp-Ser-Asp-Arg-Leu-Ile-Ile-OH, MW= 1152.3.

KTX-1001, also referred to as NSD2 inhibitor 161, is an innovative and potent inhibitor of nuclear SET domain-containing protein 2 (NSD2). This compound specifically binds to NSD2, inhibiting its catalytic activity and the mono- and dimethylation of histone H3 lysine 36 (H3K36). Such regulation impacts gene expression involved in cellular processes, including proliferation, which may subsequently slow cancer cell growth. NSD2 is part of the NSD family of histone lysine methyltransferases, which are often overexpressed and dysregulated in various cancer types.

UNC8153 TFA is a selective and potent NSD2 protein degrader with anticancer activity.UNC8153 TFA induces NSD2 degradation in MM.1S multiple myeloma cells and inhibits the proliferation of MM.1S cells.